antiplatelet


Also found in: Dictionary.
Related to antiplatelet: antiplatelet antibody

an·ti·plate·let

(an'tē-plāt'let),
A substance that manifests a lytic or agglutinative action on blood platelets, thereby inhibiting or destroying the effects of the latter.

antiplatelet

(ăn′tē-plāt′lĭt, ăn′tī-)
adj.
Acting against or destroying blood platelets.

antiplatelet

[-plat′lit]
any agent that destroys platelets or inhibits their function.

antiplatelet

directed against or destructive to blood platelets; inhibiting platelet function.

antiplatelet antibody
autoantibody against platelets, the cause of immune-mediated thrombocytopenia. Detected by the platelet factor 3 release test.
antiplatelet drugs
the prevention of thromboembolic disorders in animals is limited mainly to the treatment of cats with arterial thromboembolism and dogs with heartworms. Platelet aggregation may be impeded by treatment with aspirin, dipyrimadole, sulfinpyrazone or propranolol.
References in periodicals archive ?
SAN DIEGO, May 8, 2015 /PRNewswire/ -- A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive antiplatelet medication after percutaneous coronary intervention (PCI), according to results of the TRIAGE study presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
The patient consented enrolment in the trial, and was randomized to one of the two treatment arms involving either three months or 12 months of Dual Antiplatelet Therapy (DAPT).
EfientA is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited.
assessing compliance with treatment, stent thrombosis, very high-risk patients--all of which are situations that were not evaluated in the ARCTIC (Double Randomization of a Monitoring Adjusted Antiplatelet Treatment versus a Common Antiplatelet Treatment for DES Implantation, and Interruption versus Continuation of Double Antiplatelet Therapy) trial.
The goal of the current study was to perform a systematic review of the literature to determine if administering intravesical BCG in patients on oral anticoagulant or antiplatelet medications affects the prognosis.
These results suggest that indole-3-carbinol can be a potent antithrombotic agent with antiplatelet activity through the inhibition of GP IIb/IIIa receptor and thromboxane B2 formation.
For individuals taking antiplatelet medications, platelet reactivity testing measures levels of platelet reactivity.
The anticipated reduction in cost is expected to keep the drug on its perch as the leading nonaspirin antiplatelet agent, experts agree.
Also, we were first in the state of Arkansas to have access to some of the newest stents, cath lab devices, antiplatelet drugs, and endografts.
A large clinical trial (n=1358) involving hospitalized patients admitted with an acute coronary syndrome placed patients into three groups: those who had never taken an oral antiplatelet agent [nonusers] (n=930), those with a history of prior use (n=355) and those who had recently discontinued use (n=73).
This review included advice for patients with TAVI who present for non-cardiac surgery, stating that antiplatelet drugs could be stopped and that full heparinisation was not needed in such cases.
Aspirin, ticlopidine and the combination of dipyridamole plus aspirin are all effective antiplatelet agents for secondary stroke prevention.